MAOA and early-onset autosomal dominant Alzheimer disease: Biological activities of further IAs, isolated and tested in connection with potential treatment of Alzheimer’s disease, from 2010 (alkaloids only included with an IC50 value ≤ 30 μM for AChE or BuChE; an IC50 ≤ 200 μM for POP; all results for MAO-A and inhibition of Aβ-aggregation are included).